Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) announced its participation in a fireside chat at the Stifel 2023 Virtual CNS Days on March 29, 2023, at 12:30 p.m. ET. This event will showcase the company's novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease treatment. The live webcast will be accessible through the Investors tab on www.acumenpharm.com and will be archived for 14 days.

Acumen is advancing its investigational product candidate, ACU193, a monoclonal antibody in a Phase 1 clinical trial focused on early Alzheimer’s patients.

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Wednesday, March 29, 2023 at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

 

FAQ

When will Acumen Pharmaceuticals participate in the Stifel 2023 Virtual CNS Days?

Acumen Pharmaceuticals will participate on March 29, 2023, at 12:30 p.m. ET.

Where can I watch the Acumen Pharmaceuticals fireside chat?

The fireside chat will be available on the Investors tab of www.acumenpharm.com.

What is the focus of Acumen Pharmaceuticals' investigational product ACU193?

ACU193 targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease.

How long will the Acumen Pharmaceuticals webcast be archived?

The webcast will be archived for 14 days after the event.

What type of company is Acumen Pharmaceuticals?

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on Alzheimer’s disease therapies.